1 reports of this reaction
2.2% of all ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY reports
#8 most reported adverse reaction
APPLICATION SITE DISCOLOURATION is the #8 most commonly reported adverse reaction for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, manufactured by The Procter & Gamble Manufacturing Company. There are 1 FDA adverse event reports linking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY to APPLICATION SITE DISCOLOURATION. This represents approximately 2.2% of all 45 adverse event reports for this drug.
Patients taking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY who experience application site discolouration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE DISCOLOURATION is a less commonly reported adverse event for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, but still significant enough to appear in the safety profile.
In addition to application site discolouration, the following adverse reactions have been reported for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY:
The following drugs have also been linked to application site discolouration in FDA adverse event reports:
APPLICATION SITE DISCOLOURATION has been reported as an adverse event in 1 FDA reports for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE DISCOLOURATION accounts for approximately 2.2% of all adverse event reports for ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, making it a notable side effect.
If you experience application site discolouration while taking ALUMINUM ZIRCONIUM PENTACHLOROHYDREX GLY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.